IMA Group has expanded its capabilities in aseptic processing and high-containment technologies through the acquisition of a majority stake in ProSys Sampling Systems.
Two months after the acquisition, pharmaceutical equipment provider IMA has given Cleanroom Technology some insights into the progress of the integration.
In 2026, Ireland-based ProSys has established itself as a specialist supplier of isolator and sampling equipment to the global biopharmaceutical market.
As of Prosys' acquisition by IMA in Febraury, co-founder Michael McLoughlin has remained as Managing Director, with the company continuing to operate independently while collaborating closely with Michele Arduini, Managing Director of IMA Life.
Giacomo Guidi, Strategic Marketing and Aseptic Processing Specialist at IMA Life, told Cleanroom Technology, that early collaboration has prioritised commercial alignment over full integration.
“In the initial period, the collaboration has focused on joint account alignment and opportunity mapping,” he said, particularly for customers seeking “integrated aseptic fill-finish and containment solutions.”
Guidi added that activity so far has centred on “technical feasibility discussions and coordinated proposals rather than full operational execution.”
Priority areas include high-containment isolators for ADCs, integrated isolator-freeze dryer solutions, next-generation glove testing, and automation for ATMP and Cell & Gene Therapy applications
IMA Life has deliberately maintained ProSys’s operational autonomy while introducing targeted coordination. “We have preserved ProSys’s operational independence,” Guidi explained, while initiating “product portfolio positioning, commercial alignment, and technical knowledge sharing.”
Early steps include
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Cleanroom Technology.
Subscribe now Already a subscriber? Sign in here.